Immunic, Inc. (IMUX) Research

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

Market snapshot

Symbol
IMUX
Price
$14.20
Day change
0.00%
Market cap
$140.1M
P/E ratio
-4.10x
52-week range
5.06-15.77
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$14.50

Recent news

  • As SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company

    Prediction market traders are pricing a 78% chance that SpaceX closes its first day of trading above $2 trillion, a valuation that would rank it among the...

  • Immunic presents new vidofludimus calcium data at multiple sclerosis conference

    Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.

  • Immunic presents new vidofludimus calcium data at multiple sclerosis conference

    Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in...

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Biomea Fusion, Inc. (BMEA)
  • Cibus, Inc. (CBUS)
  • Lite Strategy, Inc. (LITS)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • Relmada Therapeutics, Inc. (RLMD)
  • Repare Therapeutics Inc. (RPTX)

Recent insider activity

  • Lundgren Erik — A-Award (1000000 shares) on 2026-05-22
  • Lundgren Erik — trade (0 shares) on 2026-06-01
  • BONNEY MICHAEL W — trade (0 shares) on 2026-05-16
  • Panzara Michael A. — A-Award (300000 shares) on 2026-04-24
  • Panzara Michael A. — trade (0 shares) on 2026-04-24

Open Immunic, Inc. (IMUX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.